Eczema Free Forever™ Eczema Free Forever™

Atopic dermatitis: From guidelines to practice

As some elements of current atopic dermatitis guidelines are now outdated due to the speed of clinical advances in the field, experts are bridging the gap with new consensus statements and scientific updates that tackle key questions regarding topical and systemic therapy.
Modern medicine – American Academy of Dermatology

Drugs in Perspective: Otezla (apremilast)

Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. On September 23, 2014, it was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Modern medicine – American Academy of Dermatology